Potential economic impact of increasing low dose aspirin usage on CVD in the US
| Autor: | Feng Pan, A. Mark Fendrick, Agnes Benedict, K.U. Wittrup-Jensen, Stephanie C. Manson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Cost-Benefit Analysis Population Guidelines as Topic Chemoprevention Angina Young Adult Cost Savings Medicine Humans cardiovascular diseases Myocardial infarction education Adverse effect Stroke Cause of death Aged Aged 80 and over Aspirin education.field_of_study Framingham Risk Score Dose-Response Relationship Drug business.industry General Medicine Middle Aged medicine.disease United States Primary Prevention Models Economic Cardiovascular Diseases Emergency medicine Physical therapy Patient Compliance Female business Gastrointestinal Hemorrhage medicine.drug |
| Zdroj: | Current medical research and opinion. 26(10) |
| ISSN: | 1473-4877 |
| Popis: | Cardiovascular disease (CVD) is a leading cause of death in the US and Western Europe, but regular use of preventive low-dose aspirin has proven effective in preventing CVD events. The purpose of this study was to explore the potential economic impact in the US if preventive aspirin usage were to be increased in line with clinical guidelines for primary and secondary prevention.The risk profile of the US population was characterized using NHANES data, and Framingham cardiovascular risk equations were applied to calculate risk for myocardial infarction, angina and ischemic stroke according to age and gender. Primary and secondary patients were considered separately. Using publicly available unit costs, a budget impact model calculated the annual impact of increased preventive aspirin usage considering gastrointestinal bleeding and hemorrhagic stroke adverse events and diminishing aspirin adherence over a 10-year time horizon.In a base population of 1,000,000 patients, full implementation of clinical guidelines would potentially prevent an additional 1273 myocardial infarctions, 2184 angina episodes and 565 ischemic strokes in primary prevention patients and an additional 578 myocardial infarctions, and 607 ischemic strokes in secondary prevention patients. This represents a total savings of $79.6 million for primary prevention and $32.2 million for secondary and additional out-of-pocket expense to patients of $29.0 million for primary prevention and $2.6 million for secondary prevention for the cost of aspirin.This budgetary model suggests that there is a strong economic case, both for payers and society, to encourage aspirin use for patients at appropriate risk and per clinical guidelines. It also provides an example of how minimizing costs do not necessarily have to imply a rationing of care. Limitations include the exclusion of other CVD interventions in the analysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|